secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001213900-23-008959
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Citius shareholders elect directors, approve 2023 equity plan, ratify auditor
-----------------------------------------------------------------------------

- All seven director nominees elected; Myron Holubiak received 27,833,866 for votes, 1,956,427 withheld; 45,937,200 broker non-votes.
- 2023 Omnibus Stock Incentive Plan approved with 22,065,354 for, 6,944,243 against, 780,696 abstain, 45,937,200 broker non-votes.
- Ratification of Wolf & Company, P.C. as independent auditor for fiscal 2023 passed with 73,110,304 for, 1,546,136 against, 1,071,053 abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/0001213900-23-008959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023008959/ea172894-8k_citiuspharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-008959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer